Diagnostic value of interleukin-8 in colorectal cancer: A case-control study and meta-analysis

Table 1 Characteristics of included studies

Study	Country	Design	Male	Age (yr)	No. of participants	Sensitivity	Specificity	TP	FP	FN	TN	QUADAS
			(%)									score
Pengjun et al[11], 2013	China	Case-control	52.4	31-74	149 CRC, 93 colorectal adenoma, 69 controls	0.869	0.971	149	2	23	69	12
				(mean 58.0)
Kantola et al[18], 2012	Finland	Case-control	51.0	Mean 67.9	148 CRC, 86 controls	0.809	0.821	115	18	27	84	12
Bünger et al[10], 2012	Germany	Case-control	52.3	40.5-99.1	164 CRC, 34 colorectal adenomas, 119 controls	0.220	0.900	81	6	287	52	12
				(mean 69.6)
Bünger et al[19], 2011	Germany	Case-control	52.0	38-88	50 CRC, 50 controls	0.280	0.940	50	3	129	50	12
				(mean 71.2)
Kaminska et al[20], 2005	Poland	Case-control	49.0	32-82	157 CRC, 50 controls	0.883	0.580	157	36	21	50	11
Current study	China	Case-control	52.1	Mean 55.4	48 CRC, 37 controls	0.854	0.541	41	17	7	20	12

TP: True positive; FP: False positive; TN: True negative; FN: False negative; QUADAS: Quality assessment of diagnostic accuracy studies; CRC: Colorectal cancer.

Table 2 Sensitivity and subgroup analyses

	Cases/controls	Sensitivity	SEN heterogeneity	Specificity	SPE heterogeneity	Positive LR	Negative LR	Diagnostic OR
			(χ2/γ/P/I2)		(χ2/γ/P/I2)
Sensitivity analysis
All studies	716/411	0.69 (0.42-0.87)	484.33/5.00/0.00/98.97%	0.85 (0.68-0.94)	69.59/5.00/0.00/92.81%	3.51	0.33	12.03
Results without two from Bunger	502/242	0.86 (0.82-0.88)	3.56/3.00/0.31/15.71%	0.79 (0.52-0.93)	43.51/3.00/0.00/93.10%	3.81	0.20	20.53
Subgroup analysis
Asia	197/106	0.86 (0.81-0.91)	0.05/1.00/0.83/0.00%	0.82 (0.74-0.89)	31.20/1.00/0.00/96.8%	7.34	0.18	37.74
Europe	519/305	0.58 (0.25-0.85)	322.69/3.00/0.00/99.07%	0.85 (0.68-0.93)	34.56/3.00/0.00/91.32%	3.01	0.43	7.91

SEN: Sensitivity; SPE: Specificity; LR: Likelihood ratio; OR: Odds ratio.